Investigational therapies targeted to the treatment of benign prostatic hyperplasia

Bibliography

• Abrams P, Cardozo L, Fall M, The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee on the International Continence Society. Urology 2003;61:37-49
   PubMed Web of Science ®Google Scholar
• Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256-61
   PubMed Web of Science ®Google Scholar
• Chute CG, Panser LA, Girman CJ, The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-9
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, European Association of Urology (EAU) Guidelines on non-neurogenic treatment of male LUTS. Available from: http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf [Accessed August 2012]
   Google Scholar
• McVary K, Roehrborn CG, Avins AL, Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803
   PubMed Web of Science ®Google Scholar
• MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005;66:780-8
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Mac Donold R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003(1):CD002081
   Google Scholar
• Wilt TJ, Howe RW, Rutks I, Terazosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002(4):CD003851
   Google Scholar
• Djavan B, Chapple C, Milani S, State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59
   PubMed Web of Science ®Google Scholar
• Kawabe K, Yoshida M, Homma Y; Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24
   PubMed Web of Science ®Google Scholar
• Marks LS, Gittelman MC, Hill LA, Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 Phase 3 studies. J Urol 2009;181:2634-40
   PubMed Web of Science ®Google Scholar
• Chapple CR, Montorsi F, Tammela TL, European Silodosin Study Group. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011;59:342-52
   PubMed Web of Science ®Google Scholar
• Carson C III, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61(Suppl 1):2-7
   PubMed Web of Science ®Google Scholar
• Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag 2009;5:535-45
   PubMedGoogle Scholar
• Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs 2008;68:463-85
   PubMed Web of Science ®Google Scholar
• Nickel JC, Gilling P, Tammela T, Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388-94
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-31
   PubMed Web of Science ®Google Scholar
• Seftel AD, de la Rosette J, Birt J, Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2012;67(1):32-45
   PubMed Web of Science ®Google Scholar
• Gacci M, Eardley I, Giuliano F, Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-25
   PubMed Web of Science ®Google Scholar
• Gacci M, Corona G, Salvi M, A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to Benign Prostatic Hyperplasia. Eur Urol 2012;61:994-1003
   PubMed Web of Science ®Google Scholar
• Oelke M, Giuliano F, Mirone V, Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-25
   PubMed Web of Science ®Google Scholar
• Chung JH, Kang DH, Oh CY, Safety and efficacy of once daily administration of 50 mg of mirodenafil to patients with erectile dysfunction: a multicenter, double-blind, placebo-controlled trial. J Urol 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Gacci M, Vittori G, Tosi N, A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 2012;9:1624-33
   PubMed Web of Science ®Google Scholar
• Chung BH, Lee JY, Lee SH, Safety and efficacy of the simultaneous administration of udenafil and an a-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009;21:122-8
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Gokce A, Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. Curr Drug Metab 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-7
   PubMed Web of Science ®Google Scholar
• Debruyne F, Tzvetkov M, Altarac S, Geavlete PA. Dose-ranging study of the luteinizing hormone releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 2010;76:927-33
   PubMed Web of Science ®Google Scholar
• Rick FG, Schally AV, Block NL, LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011;71:736-47
   PubMed Web of Science ®Google Scholar
• Rick FG, Szalontay L, Schally AV, Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 2012;187:1498-504
   PubMed Web of Science ®Google Scholar
• Maclean C, Larsen F, Drewe J, Efficacy and safety of teverelix LA, a new GnRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomized, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 60 mg at 48 hours interval administered s.c. to treatment naive patients suffering from BPH. Eur Urol Suppl 2007;6:109
   Web of Science ®Google Scholar
• Maclean CM, Skillern L, Larsen F, Efficacy and safety of teverelix LA, a new GnRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomised, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 30 mg or 60 mg (separated by at least 12 weeks) administered sc to treatment naive patients suffering from BPH. Eur Urol 2008;7(Suppl):170
   Web of Science ®Google Scholar
• Debruyne F. The efficacy and safety of ozarelix, a novel GnRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) [abstract 1552]. AUA 2007. J Urol 2007;177(Suppl):512
   Google Scholar
• Shore N. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2010;19:305-10
   PubMed Web of Science ®Google Scholar
• Shore N, Freedman S, Kalota S, Multi-center prospective randomized double-blind study of single-injection transrectal NX-1207 in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the South Central Section of the American Urological Association; 10 September 2007; Boston, USA
   Google Scholar
• Shore N, Wachs B, Wurzel R, A prospective randomized two dose level comparison of single-injection transrectal intraprostatic NX-1207 and finasteride in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the North Central Section of the American Urological Association; 25 September 2008; Chicago, USA
   Google Scholar
• Williams SA, Merchant RF, Garrett-Mayer E, A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376-85
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Egerdie B, Steinhoff G, Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-54
   PubMed Web of Science ®Google Scholar
• Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 2010;79:591-617
   PubMed Web of Science ®Google Scholar
• Chuang YC, Huang CC, Kang HY, Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006;175:1158-63
   PubMed Web of Science ®Google Scholar
• Lin AT, Yang AH, Chen KK. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007;52:582-9
   PubMed Web of Science ®Google Scholar
• Nishiyama Y, Yokoyama T, Tomizawa K, Effects of purified newly developed botulinum neurotoxin type A in rat prostate. Urology 2009;74:436-9
   PubMed Web of Science ®Google Scholar
• Silva J, Pinto R, Carvallho T, Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat. Eur Urol 2009;56:134-40
   PubMed Web of Science ®Google Scholar
• Chuang YC, Chiang PH, Huang CC, Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 2005;66:775-9
   PubMed Web of Science ®Google Scholar
• Marchal C, Perez JE, Herrera B, The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012;31:86-92
   PubMed Web of Science ®Google Scholar
• Crawford ED, Hirst K, Kusek JW, Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 2011;186:965-70
   PubMed Web of Science ®Google Scholar
• Marberger M, Chartier-Kastler E, Egerdie B, A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 2012; [Epub ahead of print]
   Google Scholar
• Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann NY Acad Sci 2010;1193:146-52
   PubMed Web of Science ®Google Scholar
• Montorsi F, Colli E. Elocalcitol in the treatment of BPH: a multicenter, randomized, placebo-controlled phase IIb clinical trial [abstract 2035]. AUA 2008. J Urol 2008;179(Suppl):700-1
   Web of Science ®Google Scholar
• Streng T, Andersson KE, Hedlund P, Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int 2012;110:E125-31
   PubMed Web of Science ®Google Scholar
• Norman BH, Dodge JA, Richardson TI, Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem 2006;49:6155-7
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs 2010;15:159-74
   PubMed Web of Science ®Google Scholar